Kinnate Biopharma Inc is a biotechnology business based in the US. Kinnate Biopharma shares (KNTE) are listed on the NASDAQ and all prices are listed in US Dollars. Kinnate Biopharma employs 52 staff and has a market cap (total outstanding shares value) of 0.00.
How to buy shares in Kinnate Biopharma
- Compare share trading platforms.Use our comparison table to help you find a platform that fits you.
- Open your brokerage account. Complete an application with your details.
- Confirm your payment details. Fund your account.
- Research the stock. Find the stock by name or ticker symbol – KNTE – and research it before deciding if it's a good investment for you.
- Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
- Check in on your investment. Optimize your portfolio by tracking your stock.
Kinnate Biopharma stock price (NASDAQ: KNTE)Use our graph to track the performance of KNTE stocks over time.
Kinnate Biopharma shares at a glance
|Latest market close||$23.14|
|52-week range||$17.58 - $48.75|
|50-day moving average||$23.01|
|200-day moving average||$23.58|
|Wall St. target price||$47.00|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$-2.37|
Buy Kinnate Biopharma shares from these brokeragesCompare special offers, low fees and a wide range of types of investments among top trading platforms.
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
Is it a good time to buy Kinnate Biopharma stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Kinnate Biopharma price performance over time
|1 week (2021-10-15)||-0.22%|
|1 month (2021-09-22)||-1.28%|
|3 months (2021-07-22)||7.68%|
|6 months (2021-04-22)||-12.68%|
|1 year (2020-10-18)||N/A|
|2 years (2019-10-18)||N/A|
|3 years (2018-10-18)||N/A|
|5 years (2016-10-18)||N/A|
Kinnate Biopharma financials
|Gross profit TTM||$0|
|Return on assets TTM||-9.41%|
|Return on equity TTM||-15.25%|
|Market capitalisation||$1 billion|
TTM: trailing 12 months
Shorting Kinnate Biopharma shares
There are currently 2.0 million Kinnate Biopharma shares held short by investors – that's known as Kinnate Biopharma's "short interest". This figure is 11.4% up from 1.8 million last month.
There are a few different ways that this level of interest in shorting Kinnate Biopharma shares can be evaluated.
Kinnate Biopharma's "short interest ratio" (SIR)
Kinnate Biopharma's "short interest ratio" (SIR) is the quantity of Kinnate Biopharma shares currently shorted divided by the average quantity of Kinnate Biopharma shares traded daily (recently around 199994.42231076). Kinnate Biopharma's SIR currently stands at 10.04. In other words for every 100,000 Kinnate Biopharma shares traded daily on the market, roughly 10040 shares are currently held short.
To gain some more context, you can compare Kinnate Biopharma's short interest ratio against those of similar companies.
However Kinnate Biopharma's short interest can also be evaluated against the total number of Kinnate Biopharma shares, or, against the total number of tradable Kinnate Biopharma shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Kinnate Biopharma's short interest could be expressed as 0.05% of the outstanding shares (for every 100,000 Kinnate Biopharma shares in existence, roughly 50 shares are currently held short) or 0.1207% of the tradable shares (for every 100,000 tradable Kinnate Biopharma shares, roughly 121 shares are currently held short).
A SIR above 10% would generally be considered pretty high, pointing to a potentially pessimistic outlook for the share price and a discouraging interest in betting against Kinnate Biopharma.
Find out more about how you can short Kinnate Biopharma stock.
Kinnate Biopharma share dividends
We're not expecting Kinnate Biopharma to pay a dividend over the next 12 months.
You may also wish to consider:
- Amgen (AMGN.US) (3.25% forward annual dividend yield)
Kinnate Biopharma overview
Kinnate Biopharma Inc. , a biopharmaceutical company, focuses on the discovery and development of small molecule kinase inhibitors to treat genomically defined cancers. It develops KIN-2787, which is a rapidly accelerated fibrosarcoma inhibitor for the treatment of patients with lung cancer, melanoma, and other solid tumors; KIN-3248 small-molecule kinase inhibitors that target cancer-associated alterations in fibroblast growth factor receptors (FGFR)2 and FGFR3 genes; and small molecule research programs, including a Cyclin-Dependent Kinase 12 inhibitor in its KIN004 program. The company was incorporated in 2018 and is headquartered in San Diego, California. .
Kinnate Biopharma in the news
We're Not Very Worried About Kinnate Biopharma's (NASDAQ:KNTE) Cash Burn Rate
Kinnate Biopharma Inc. Details Two-Part Phase 1 Trial Design for its Lead RAF Kinase Inhibitor Program at the AACR-NCI-EORTC Virtual International Conference
Kinnate Biopharma Inc :. Details Two-Part Phase 1 Trial Design for its Lead RAF Kinase Inhibitor Program at the AACR-NCI-EORTC Virtual International Conference
Frequently asked questionsWhat percentage of Kinnate Biopharma is owned by insiders or institutions?
Currently 15.022% of Kinnate Biopharma shares are held by insiders and 87.882% by institutions. How many people work for Kinnate Biopharma?
Latest data suggests 52 work at Kinnate Biopharma. When does the fiscal year end for Kinnate Biopharma?
Kinnate Biopharma's fiscal year ends in December. Where is Kinnate Biopharma based?
Kinnate Biopharma's address is: 11975 El Camino Real, San Diego, CA, United States, 92130 What is Kinnate Biopharma's ISIN number?
Kinnate Biopharma's international securities identification number is: US49705R1059
More guides on Finder
How to buy Valkyrie Bitcoin Strategy ETF (BTFD)
Steps to owning and managing Valkyrie Bitcoin Strategy ETF units.
Today’s top US stocks: KE Holdings ADRs (BEKE ↑9.1%), Futu Holdings ADRs (FUTU ↑7.8%)
See the 10 biggest gainers on the New York Stock Exchange and Nasdaq on Oct. 21, 2021
How to buy ProShares Bitcoin Strategy ETF (BITO)
Steps to owning and managing ProShares Bitcoin Strategy ETF units.
How to buy The Real Good Food Company (RGF) stock when it goes public
Everything we know about the The Real Good Food Company IPO, plus information on how to buy in.
How to buy Lulu’s Fashion Lounge Holdings (LVLU) stock when it goes public
Everything we know about the Lulu’s Fashion Lounge Holdings IPO, plus information on how to buy in.
How to buy Allarity Therapeutics (ALLR) stock when it goes public
Everything we know about the Allarity Therapeutics IPO, plus information on how to buy in.
How to buy Jupiter Neurosciences (JUNS) stock when it goes public
Everything we know about the Jupiter Neurosciences IPO, plus information on how to buy in.
How to buy Mainz Biomed (MYNZ) stock when it goes public
Everything we know about the Mainz Biomed IPO, plus information on how to buy in.
How to buy Progressive Care stock when it goes public
Everything we know about the Progressive Care IPO, plus information on how to buy in.
How to buy Desert Peak Minerals (DPM) stock when it goes public
Everything we know about the Desert Peak Minerals IPO, plus information on how to buy in.
Ask an Expert